News and Events
Publication on quality of life – Pierrel demonstrates expertise in medical writing and biostatistics
Pierrel Research is once more pleased to announce a publication in the online journal “Clinical Nutrition“. This is the final step of the publication of results emerging from the CL0600-020 study, which was sponsored by Takeda GmbH.read more
Meeting of the shareholders and the board of directors of Pierrel Research International AG
- Mr. Luigi Visani, has resigned its office as CEO of Pierrel Research International AG (“Print”), in the context of the proposed integration transaction between Print and mondoBiotech AG
- Appointment of the new board of directors of Print
-...read more
Pierrel Research Announces the Imminent Presentation at the 2013 ACC Meeting in San Francisco of Results from PEITHO, the Largest Trial Ever Performed in Patients with Acute Pulmonary Embolism
Pierrel Research International AG, a wholly owned subsidiary and the Contract Research (CRO) Division of Pierrel S.p.A., is pleased to announce the imminent official presentation of results from the PEITHOread more
A new proof of Pierrel Research expertise in scale development for clinical trials
Pierrel Research is pleased to announce the publication in the “Clinical Nutrition “journal of the following study results: “Development and validation of the disease-specific Short Bowel Syndrome-Quality of Life (SBS-QoL™) scale” read more
Pierrel Research and mondoBIOTECH combine their business to create a new and innovative approach to clinical drug development
Pierrel Research announces a binding agreement with mondoBIOTECH, a Swiss–based drug discovery company focused on repurposing drugs in rare and neglected diseasesread more
Pierrel Research will attend the 6th European Business Development Conference in Dresden
Pierrel Research will participate at the Business Development Conference, Pharma and European Biotech – Alliances for Mutual Success, on 17th and 18th October in Dresden, Germanyread more
Pierrel Research confirms its strong and competitive expertise in the Oncology Area
Start of Pivotal Phase III trial for Lutathera® in cancer patients with progressive midgut carcinoidread more